Singapore markets close in 11 minutes

AMGN Jun 2025 160.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.48000.0000 (0.00%)
As of 10:51AM EDT. Market open.
Full screen
Previous close2.4800
Open2.4800
Bid0.0000
Ask0.0000
Strike160.00
Expiry date2025-06-20
Day's range2.4800 - 2.4800
Contract rangeN/A
Volume23
Open interestN/A
  • Reuters

    Sandoz reaches agreement with Amgen over patent dispute

    Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars. The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement. "The terms of the agreement will not impact our previously disclosed 2024 guidance," Sandoz said.

  • PR Newswire

    AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS

    Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

  • Zacks

    What's in the Cards for Amgen (AMGN) This Earnings Season?

    Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.